Akorn to Report First Quarter 2019 Financial Results and Host Conference Call
April 15 2019 - 1:56PM
Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic
pharmaceutical company, today announced that it plans to issue a
press release before market open on Tuesday, May 7,
2019 outlining its first quarter 2019 financial results.
In addition, the Company has scheduled a conference call
at 10:00 a.m. ET on the same day to discuss its first
quarter 2019 financial results. Hosting the call will be Douglas
Boothe, President and Chief Executive Officer and Duane Portwood,
Chief Financial Officer.
To access the call, please dial (844) 249-9382 in the U.S. and
+1 (270) 823-1530 for international callers. The conference ID is
8456 549. To access the live webcast, please go to Akorn’s Investor
Relations web site at http://investors.akorn.com.
A webcast replay of the conference call will be available
shortly following the conclusion of the call and will be available
for 90 days. To access the webcast replay, please go to Akorn’s
Investor Relations web site at http://investors.akorn.com.
About AkornAkorn, Inc. is a specialty
generic pharmaceutical company engaged in the development,
manufacture and marketing of multisource and branded
pharmaceuticals. Akorn has manufacturing facilities
located in Decatur, Illinois; Somerset, New
Jersey; Amityville, New York;
Hettlingen, Switzerland and Paonta
Sahib, India that manufacture ophthalmic, injectable and
specialty sterile and non-sterile pharmaceuticals. Additional
information is available on Akorn’s website
at www.akorn.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release includes statements that may
constitute "forward-looking statements", including expectations and
other statements regarding Akorn's goals and plans. When used in
this document, the words “will,” “expect,” “continue," “scheduled,”
“plans,” “intend,” and similar expressions are generally intended
to identify forward-looking statements. These statements are made
pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. A number of important
factors could cause actual results of Akorn and its subsidiaries to
differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to: (i) the
effect of the Delaware court’s recent decision against Akorn on
Akorn’s ability to retain and hire key personnel, its ability to
maintain relationships with its customers, suppliers and others
with whom it does business, or its operating results and business
generally, (ii) the risk that ongoing or future litigation related
to the court’s decision may result in significant costs of defense,
indemnification and/or liability, (iii) the outcome of the
investigation conducted by Akorn with the assistance of outside
consultants, into alleged breaches of FDA data integrity
requirements relating to product development at Akorn and any
actions taken by Akorn, third parties or the FDA as a result of
such investigations, (iv) the difficulty of predicting the timing
or outcome of product development efforts, including FDA and other
regulatory agency approvals and actions, if any, (v) the timing and
success of product launches, (vi) difficulties or delays in
manufacturing, and (vii) such other risks and uncertainties
outlined in the risk factors detailed in Part I, Item 1A, “Risk
Factors,” of Akorn’s Annual Report on Form 10-K for the fiscal year
ended December 31, 2018 (as filed with the Securities and Exchange
Commission (“SEC”) on March 1, 2019), and other risk factors
identified from time to time in our filings with the SEC. Readers
should carefully review these risk factors, and should not place
undue reliance on our forward-looking statements. These
forward-looking statements are based on information, plans and
estimates at the date of this report. Akorn undertakes no
obligation to update any forward-looking statements to reflect
changes in underlying assumptions or factors, new information,
future events or other changes.
Investors/Media:(847)
279-6162Investor.relations@akorn.com
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akorn (NASDAQ:AKRX)
Historical Stock Chart
From Sep 2023 to Sep 2024